A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells

Alessia Garufi, Daniela Trisciuoglio, Manuela Porru, Carlo Leonetti, Antonella Stoppacciaro, Valerio D'Orazi, Maria Laura Avantaggiati, Alessandra Crispini, Daniela Pucci, Gabriella D'Orazi

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background: Mutations of the p53 oncosuppressor gene are amongst the most frequent aberration seen in human cancer. Some mutant (mt) p53 proteins are prone to loss of Zn(II) ion that is bound to the wild-type (wt) core, promoting protein aggregation and therefore unfolding. Misfolded p53 protein conformation impairs wtp53-DNA binding and transactivation activities, favouring tumor growth and resistance to antitumor therapies. Screening studies, devoted to identify small molecules that reactivate mtp53, represent therefore an attractive anti-cancer therapeutic strategy. Here we tested a novel fluorescent curcumin-based Zn(II)-complex (Zn-curc) to evaluate its effect on mtp53 reactivation in cancer cells. Methods. P53 protein conformation was examined after Zn-curc treatment by immunoprecipitation and immunofluorescence assays, using conformation-specific antibodies. The mtp53 reactivation was evaluated by chromatin-immunoprecipitation (ChIP) and semi-quantitative RT-PCR analyses of wild-type p53 target genes. The intratumoral Zn-curc localization was evaluated by immunofluorescence analysis of glioblastoma tissues of an ortothopic mice model. Results: The Zn-curc complex induced conformational change in p53-R175H and -R273H mutant proteins, two of the most common p53 mutations. Zn-curc treatment restored wtp53-DNA binding and transactivation functions and induced apoptotic cell death. In vivo studies showed that the Zn-curc complex reached glioblastoma tissues of an ortothopic mice model, highlighting its ability to crossed the blood-tumor barrier. Conclusions: Our results demonstrate that Zn-curc complex may reactivate specific mtp53 proteins and that may cross the blood-tumor barrier, becoming a promising compound for the development of drugs to halt tumor growth.

Original languageEnglish
Article number72
JournalJournal of Experimental and Clinical Cancer Research
Volume32
Issue number1
DOIs
Publication statusPublished - 2013

Fingerprint

Curcumin
Neoplasms
Protein Conformation
p53 Genes
Mutant Proteins
Glioblastoma
Transcriptional Activation
Fluorescent Antibody Technique
Mutation
Chromatin Immunoprecipitation
DNA
Therapeutics
Growth
Immunoprecipitation
Proteins
Cell Death
Ions
Polymerase Chain Reaction
Antibodies
Pharmaceutical Preparations

Keywords

  • Cancer therapy
  • DNA binding
  • Gene expression
  • Glioblastoma
  • Mutant p53
  • p53 transcriptional activity
  • Protein conformation
  • Zinc complex

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells. / Garufi, Alessia; Trisciuoglio, Daniela; Porru, Manuela; Leonetti, Carlo; Stoppacciaro, Antonella; D'Orazi, Valerio; Avantaggiati, Maria Laura; Crispini, Alessandra; Pucci, Daniela; D'Orazi, Gabriella.

In: Journal of Experimental and Clinical Cancer Research, Vol. 32, No. 1, 72, 2013.

Research output: Contribution to journalArticle

Garufi, Alessia ; Trisciuoglio, Daniela ; Porru, Manuela ; Leonetti, Carlo ; Stoppacciaro, Antonella ; D'Orazi, Valerio ; Avantaggiati, Maria Laura ; Crispini, Alessandra ; Pucci, Daniela ; D'Orazi, Gabriella. / A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells. In: Journal of Experimental and Clinical Cancer Research. 2013 ; Vol. 32, No. 1.
@article{a8d701b9509448fd96cc004d79a441cf,
title = "A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells",
abstract = "Background: Mutations of the p53 oncosuppressor gene are amongst the most frequent aberration seen in human cancer. Some mutant (mt) p53 proteins are prone to loss of Zn(II) ion that is bound to the wild-type (wt) core, promoting protein aggregation and therefore unfolding. Misfolded p53 protein conformation impairs wtp53-DNA binding and transactivation activities, favouring tumor growth and resistance to antitumor therapies. Screening studies, devoted to identify small molecules that reactivate mtp53, represent therefore an attractive anti-cancer therapeutic strategy. Here we tested a novel fluorescent curcumin-based Zn(II)-complex (Zn-curc) to evaluate its effect on mtp53 reactivation in cancer cells. Methods. P53 protein conformation was examined after Zn-curc treatment by immunoprecipitation and immunofluorescence assays, using conformation-specific antibodies. The mtp53 reactivation was evaluated by chromatin-immunoprecipitation (ChIP) and semi-quantitative RT-PCR analyses of wild-type p53 target genes. The intratumoral Zn-curc localization was evaluated by immunofluorescence analysis of glioblastoma tissues of an ortothopic mice model. Results: The Zn-curc complex induced conformational change in p53-R175H and -R273H mutant proteins, two of the most common p53 mutations. Zn-curc treatment restored wtp53-DNA binding and transactivation functions and induced apoptotic cell death. In vivo studies showed that the Zn-curc complex reached glioblastoma tissues of an ortothopic mice model, highlighting its ability to crossed the blood-tumor barrier. Conclusions: Our results demonstrate that Zn-curc complex may reactivate specific mtp53 proteins and that may cross the blood-tumor barrier, becoming a promising compound for the development of drugs to halt tumor growth.",
keywords = "Cancer therapy, DNA binding, Gene expression, Glioblastoma, Mutant p53, p53 transcriptional activity, Protein conformation, Zinc complex",
author = "Alessia Garufi and Daniela Trisciuoglio and Manuela Porru and Carlo Leonetti and Antonella Stoppacciaro and Valerio D'Orazi and Avantaggiati, {Maria Laura} and Alessandra Crispini and Daniela Pucci and Gabriella D'Orazi",
year = "2013",
doi = "10.1186/1756-9966-32-72",
language = "English",
volume = "32",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells

AU - Garufi, Alessia

AU - Trisciuoglio, Daniela

AU - Porru, Manuela

AU - Leonetti, Carlo

AU - Stoppacciaro, Antonella

AU - D'Orazi, Valerio

AU - Avantaggiati, Maria Laura

AU - Crispini, Alessandra

AU - Pucci, Daniela

AU - D'Orazi, Gabriella

PY - 2013

Y1 - 2013

N2 - Background: Mutations of the p53 oncosuppressor gene are amongst the most frequent aberration seen in human cancer. Some mutant (mt) p53 proteins are prone to loss of Zn(II) ion that is bound to the wild-type (wt) core, promoting protein aggregation and therefore unfolding. Misfolded p53 protein conformation impairs wtp53-DNA binding and transactivation activities, favouring tumor growth and resistance to antitumor therapies. Screening studies, devoted to identify small molecules that reactivate mtp53, represent therefore an attractive anti-cancer therapeutic strategy. Here we tested a novel fluorescent curcumin-based Zn(II)-complex (Zn-curc) to evaluate its effect on mtp53 reactivation in cancer cells. Methods. P53 protein conformation was examined after Zn-curc treatment by immunoprecipitation and immunofluorescence assays, using conformation-specific antibodies. The mtp53 reactivation was evaluated by chromatin-immunoprecipitation (ChIP) and semi-quantitative RT-PCR analyses of wild-type p53 target genes. The intratumoral Zn-curc localization was evaluated by immunofluorescence analysis of glioblastoma tissues of an ortothopic mice model. Results: The Zn-curc complex induced conformational change in p53-R175H and -R273H mutant proteins, two of the most common p53 mutations. Zn-curc treatment restored wtp53-DNA binding and transactivation functions and induced apoptotic cell death. In vivo studies showed that the Zn-curc complex reached glioblastoma tissues of an ortothopic mice model, highlighting its ability to crossed the blood-tumor barrier. Conclusions: Our results demonstrate that Zn-curc complex may reactivate specific mtp53 proteins and that may cross the blood-tumor barrier, becoming a promising compound for the development of drugs to halt tumor growth.

AB - Background: Mutations of the p53 oncosuppressor gene are amongst the most frequent aberration seen in human cancer. Some mutant (mt) p53 proteins are prone to loss of Zn(II) ion that is bound to the wild-type (wt) core, promoting protein aggregation and therefore unfolding. Misfolded p53 protein conformation impairs wtp53-DNA binding and transactivation activities, favouring tumor growth and resistance to antitumor therapies. Screening studies, devoted to identify small molecules that reactivate mtp53, represent therefore an attractive anti-cancer therapeutic strategy. Here we tested a novel fluorescent curcumin-based Zn(II)-complex (Zn-curc) to evaluate its effect on mtp53 reactivation in cancer cells. Methods. P53 protein conformation was examined after Zn-curc treatment by immunoprecipitation and immunofluorescence assays, using conformation-specific antibodies. The mtp53 reactivation was evaluated by chromatin-immunoprecipitation (ChIP) and semi-quantitative RT-PCR analyses of wild-type p53 target genes. The intratumoral Zn-curc localization was evaluated by immunofluorescence analysis of glioblastoma tissues of an ortothopic mice model. Results: The Zn-curc complex induced conformational change in p53-R175H and -R273H mutant proteins, two of the most common p53 mutations. Zn-curc treatment restored wtp53-DNA binding and transactivation functions and induced apoptotic cell death. In vivo studies showed that the Zn-curc complex reached glioblastoma tissues of an ortothopic mice model, highlighting its ability to crossed the blood-tumor barrier. Conclusions: Our results demonstrate that Zn-curc complex may reactivate specific mtp53 proteins and that may cross the blood-tumor barrier, becoming a promising compound for the development of drugs to halt tumor growth.

KW - Cancer therapy

KW - DNA binding

KW - Gene expression

KW - Glioblastoma

KW - Mutant p53

KW - p53 transcriptional activity

KW - Protein conformation

KW - Zinc complex

UR - http://www.scopus.com/inward/record.url?scp=84885002384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885002384&partnerID=8YFLogxK

U2 - 10.1186/1756-9966-32-72

DO - 10.1186/1756-9966-32-72

M3 - Article

C2 - 24220325

AN - SCOPUS:84885002384

VL - 32

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 1

M1 - 72

ER -